A Phase 1b, First-in-Human, Dose Escalation and Expansion Study of XMT-1522 in Patients With Advanced Breast Cancer and Other Advanced Tumors Expressing HER2

Trial Profile

A Phase 1b, First-in-Human, Dose Escalation and Expansion Study of XMT-1522 in Patients With Advanced Breast Cancer and Other Advanced Tumors Expressing HER2

Recruiting
Phase of Trial: Phase I

Latest Information Update: 28 Mar 2018

At a glance

  • Drugs XMT 1522 (Primary)
  • Indications Adenocarcinoma; Advanced breast cancer; Gastric cancer; Non-small cell lung cancer; Solid tumours
  • Focus Adverse reactions; First in man
  • Sponsors Mersana Therapeutics
  • Most Recent Events

    • 28 Mar 2018 According to a Mersana Therapeutics media release, dosing in the seventh cohort is ongoing. Company expects to select recommended Phase 2 Dose (RP2D), substantially enroll dose expansion cohorts and to present dose escalation data at a scientific conference in 2018.
    • 08 Jan 2018 According to a Mersana Therapeutics media release, the dose escalation phase of the study and recruitment in the dose expantion phase is expect to complete in 2018. Till now, dosing in 6 cohorts of dose escalation phase has been completed. Data is expected to present at a scientific conference.
    • 11 Aug 2017 Interim safety results from this trial are expected around the end of 2017 according to a Mersana Therapeutics media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top